Scientist II/Senior Scientist – Protein Sciences
Nurix, Inc. is a science-minded yet goal-oriented organization that is focused on bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation, a function vital to the healthy life of a cell, uncovering therapeutic opportunities in multiple disease areas. The Nurix scientific team has established an innovative drug discovery platform to enable the discovery of selective small molecule inhibitors or activators of the UPS, enabling the discovery of new class of drugs that can restore normal cellular homeostasis. In September 2015, Nurix entered into a multiyear collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis. The collaboration encompasses oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix was founded by internationally recognized experts in the ubiquitin proteasome field and is funded by leading life science investors, Third Rock Ventures, The Column Group, and a multi-year strategic collaboration with Celgene. The company is based in San Francisco, California.